

SESLHD PROCEDURE COVER SHEET



Health
South Eastern Sydney
Local Health District

NAME OF DOCUMENT	Medication – Safety Alerts, Notices and Information
TYPE OF DOCUMENT	Procedure
DOCUMENT NUMBER	SESLHDPR/724
DATE OF PUBLICATION	March 2025
RISK RATING	Medium
LEVEL OF EVIDENCE	National Safety and Quality Health Services Standards: Standard 1 – Clinical Governance
REVIEW DATE	March 2028
FORMER REFERENCE(S)	SESLHDPR/319 - Product – Clinical product Notices Recalls and Safety Alerts PD 102 Product – Clinical Recalls and Alerts
EXECUTIVE SPONSOR or EXECUTIVE CLINICAL SPONSOR	Director, Clinical Governance and Medical Services
AUTHOR	Erica Wales SESLHD Quality Use of Medicines Lead Pharmacist
POSITION RESPONSIBLE FOR THE DOCUMENT	SESLHD Quality Use of Medicines Lead Pharmacist, Clinical Governance and Medical Services SESLHD-DrugCommittee@health.nsw.gov.au
FUNCTIONAL GROUP(S)	Clinical Governance Medicines and Therapeutics Related Policy Documents
KEY TERMS	Medication, medicine, drug, safety alert broadcasting system
SUMMARY	This procedure outlines the process for managing all medication safety alerts, notices and information in SESLHD.

COMPLIANCE WITH THIS DOCUMENT IS MANDATORY

**This Procedure is intellectual property of South Eastern Sydney Local Health District.
Procedure content cannot be duplicated.**

Feedback about this document can be sent to SESLHD-Policy@health.nsw.gov.au

SESLHD PROCEDURE

Medication – Safety Alerts, Notices and Information

SESLHDPR/724

1. POLICY STATEMENT

This procedure outlines the process to be undertaken in SESLHD to ensure compliance with [NSW Health Policy Directive PD2024_016 - System-level patient safety risks: Response co-ordination and communication](#) and to ensure that all safety alerts, notices and information related to medicines from external sources including the Ministry of Health (MOH); Clinical Excellence Commission (CEC); Therapeutic Goods Association (TGA) or suppliers and vendors are appropriately disseminated, monitored and actioned.

This procedure does not include the Drug Recall Process which is addressed in [SESLHDPR/438 - Medicine Recall Process](#).

This procedure does not include information safety alerts, notices and information related to biologicals or medical devices which is addressed in [SESLHDPR/319 - Product – Clinical Product Notices, Recalls and Safety Alerts](#).

2. BACKGROUND

SESLHD receives product safety alerts, notifications and information from the Clinical Excellence Commission (CEC), as well as from individual suppliers and vendors directly to individual facilities and departments, on occasion. The CEC distributes a daily tranche via QARS ReACT at 9am each business day. The emails are sent to SESLHD-Mail@health.nsw.gov.au.

The Safety Alert Broadcast System (SABS) notifications are issued by the MOH and CEC as per [NSW Health Policy Directive PD2013_009 - Safety Alert Broadcast System](#). These consist of a three-tiered approach to distribution, prioritisation and management.

Safety Alert – The aim of a safety alert is to quickly disseminate information to health services about a safety matter requiring immediate attention and action which may include a **product recall**. The colour coding for safety alerts is **RED**.

Safety Notice – The aim of a safety notice is to inform health services about potential quality and safety issues requiring risk assessment at the local level. The colour coding for safety notices is **AMBER**.

Safety Information – The aim of safety information is to disseminate quality and safety information to health services to ensure lessons are learnt from state, national and international sources. The colour coding for safety Information is **GREEN**.

Occasionally patient safety information is notified via a direct memo from the CEC to SESLHD mail. These are managed in a similar manner by SESLHD.

The purpose of this document is to establish a clear process within SESLHD for the management of medication related safety alerts, notices and information received.

SESLHD PROCEDURE

Medication – Safety Alerts, Notices and Information

SESLHDPR/724

3. RESPONSIBILITIES

3.1 Chief Executive will:

- Ensure there is an efficient and effective process for managing the receipt, distribution, implementation and effectiveness of medication related safety alerts, notices and information.

3.2 District Executive Services (SESLHD-Mail@health.nsw.gov.au) will:

- Catalogue all safety alerts, notices and information in Content Manager; and allocate by email to the District Clinical Governance Unit.

3.3 Director Clinical Governance (DCG) will:

- Ensure that all medication related safety alerts, notices and information are disseminated as per Appendix 1.
- Ensure all correspondence regarding the medication related safety alerts, notices and information is catalogued in Content Manager.

3.4 SESLHD DTC delegate - Quality Use of Medicines (QUM) Lead Pharmacist will:

- Receive all medication related safety alerts, notices and information.
- Ensure dissemination of all medication related safety alerts, notices and information as per Appendix 1.
- Notify District CGU when medication related safety alerts, notices and information are disseminated and actioned (within 2 weeks unless required more urgently).
- Ensure a response is provided to the CEC when requested.
- On behalf of the SESLHD Drug and Therapeutics Committee (DTC), record implementation of nominated actions and monitor risks to the SESLHD in relation to medication related safety alerts, notices and information.
- Ensure all correspondence regarding the medication related safety alerts, notices or information is appropriately recorded and documented.
- In their absence (i.e. planned or unplanned leave) delegate these responsibilities.

3.5 General Manager/ Service Directors will:

- Ensure that Cost Centre Managers affected by the medication related safety alerts, notices or information act in accordance with this procedure.
- Notify the DCG of any medication related safety alerts, notices or information received directly to the hospital.
- Ensure that any medication related risks to the organisation are reported to the SESLHD DTC (via email SESLHD-DrugCommittee@health.nsw.gov.au).
- Ensure there is completion of acknowledgement forms and a response, if requested, provided to SESLHD-DrugCommittee@health.nsw.gov.au
- When required After Hours, notify affected departments within their facilities immediately as per section 4.3.

SESLHD PROCEDURE

Medication – Safety Alerts, Notices and Information

SESLHDPR/724

3.6 Local site/service medication related committees will:

- When required by the SESLHD DTC Action Plan, ensure that medication related safety alerts, notices or information are tabled at the local site/service medication related committees and are acted on in accordance with this procedure.

3.7 CPIU Managers will:

- When required by the SESLHD DTC Action Plan, ensure that medication related safety alerts, notices or information are acted on in accordance with this procedure.

3.8 Cost Centre Managers will:

- Send any medication related information that was not received in the department via the Clinical Governance Unit to SESLHD-Mail@health.nsw.gov.au to ensure the District is aware and can coordinate the response to any District risks.
- When required by the SESLHD DTC Action Plan, ensure that medication related safety alerts, notices or information are acted on in accordance with this procedure.

3.9 District Director Pharmacy Services, Directors of Pharmacy and Pharmacy Business Manager will:

- Provide any additional information concerning medication related safety alerts, notices or information to the SESLHD DTC (via email SESLHD-DrugCommittee@health.nsw.gov.au) for further dissemination.

SESLHD PROCEDURE

Medication – Safety Alerts, Notices and Information

SESLHDPR/724

4. PROCEDURE

4.1 Receipt of Medication Related Safety Alerts, Notices or Information

A medication related safety alerts, notices or information will usually be received from the Clinical Excellence Commission (CEC), using QARS ReACT.

Occasionally companies will contact facilities directly. In this instance, information should be sent to the District Clinical Governance Unit via SESLHD-Mail@health.nsw.gov.au to be entered into Content Manager.

4.2 Dissemination of Medication Related Safety Alerts, Notices or Information

Upon receipt from SESLHD mail, District CGU will process the medication related safety alerts, notices or information by creating a new container in Content Manager, update Safety Alert Database and create a Safety Alert Response Form.

All medication related safety alerts, notices or information will be sent by the District CGU to the SESLHD DTC (via email SESLHD-DrugCommittee@health.nsw.gov.au) for review and the District Director of Pharmacy Service for their information. The SESLHD DTC delegate, QUM Lead Pharmacist, will disseminate to the appropriate persons for acknowledgement and coordinate the response for tabling at the SESLHD Drug and Therapeutics Committee.

The medication related safety alerts, notices or information will be sent on behalf of the SESLHD DTC, by the QUM Lead Pharmacist, to medication related committees, General Managers and CPIU Managers at each facility for their information.

The TGA Distribution Lists for recall notices are commercially sensitive and are not to be distributed further.

If no SESLHD sites are affected, the medication related safety alerts, notices or information is saved in a separate Content Manager container.

4.3 Actions for Local Site/Service

Actions at the local site/service occur at the request of the SESLHD DTC in accordance with the management pathway (see appendix 1)

- **GREEN** and **AMBER** pathway: information must be tabled at the next local site/service medication related committee meeting. No further action is required unless explicitly stated.
- **RED** pathway: information must be tabled at the next local site/service medication related committee and a coordinated response returned to SESLHD-DrugCommittee@health.nsw.gov.au. When requested, the local site/service medication related committee must develop a local action plan.

SESLHD PROCEDURE

Medication – Safety Alerts, Notices and Information

SESLHDPR/724

4.4 After Hours Procedure on Receipt of Medication Related Safety Alerts, Notices or Information

Out of business hours, the MOH or CEC will contact the CE by telephone should there be a need to disseminate an urgent medication related safety alert.

The General Manager/ Service Director, Executive On-Call and AH Nurse Manager, when advised of urgent medication related safety alerts, will contact the relevant On-Call Pharmacist and refer to SESLHDPR/438 - Medicine Recall Process to ensure that the recommendations are actioned.

The QUM Lead Pharmacist, on behalf of the SESLHD DTC, will action the formal Safety Alert as per section 4.2 when received on the first day of the CEC's normal business hours.

5. DOCUMENTATION

Records to be catalogued in the Electronic Document Records Management System (HP Content Manager).

6. REPORTING

Monthly medication related safety alerts, notices and information are reported to the SESLHD Patient Safety and Quality Committee, via the SESLHD Drug and Therapeutics Committee.

7. AUDIT

The SESLHD Drug and Therapeutics Committee will monitor implementation of nominated actions and risks to the SESLHD in relation to medication related safety alerts, notices and information.

8. REFERENCES

[NSW Health Policy Directive PD2024_016 - System-level patient safety risks: Response co-ordination and communication](#)
[SESLHDPR/254 - Goods Return Advice](#)
[SESLHDPR/438 - Medicine Recall Process](#)
[SESLHDPR/319 - Product – Clinical Product Notices, Recalls and Safety Alerts](#)

9. VERSION AND APPROVAL HISTORY

Date	Version No	Author and approval notes
November 2021	Draft	Erica Wales, QUM Lead Pharmacist, SESLHD
February 2022	Draft	Approved at Quality Use of Medicines Committee. To be tabled at Clinical and Quality Council.
March 2022	1	Approved by Clinical and Quality Council.
24 March 2025	1.1	Minor review. Updated to PD2024_016 and DTC terminology. Approved by SESLHD Drug and Therapeutics Committee.

Medication – Safety Alerts, Notices and Information

SESLHDPR/724

Appendix 1 – SESLHD Medication Safety Alerts, Notice and Information Management Pathway

